deltatrials
Active Not Recruiting PHASE1 INTERVENTIONAL 3-arm NCT01822652

3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase Suicide Safety Switch, Neuroblastoma, GRAIN (GRAIN)

Autologous Activated T-Cells Transduced with a 3rd Generation GD-2 Chimeric Antigen Receptor and ICaspase9 Safety Switch Administered to Patients with Relapsed or Refractory Neuroblastoma (GRAIN)

Sponsor: Baylor College of Medicine

Conditions Neuroblastoma
Interventions Cytoxan Fludara Keytruda iC9-GD2 T Cells - fresh iC9-GD2 T Cells - frozen iC9-GD2 T cells
Updated 18 times since 2017 Last updated: Feb 21, 2025 Started: Aug 31, 2013 Primary completion: Dec 31, 2015 Completion: Oct 31, 2030
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT01822652, this PHASE1 trial focuses on Neuroblastoma and remains ongoing. Sponsored by Baylor College of Medicine, it has been updated 18 times since 2013, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~May 2018 · 15 months · monthly snapshot~May 2018 – ~Jun 2018 · 31 days · monthly snapshot~Jun 2018 – ~Nov 2018 · 5 months · monthly snapshot~Nov 2018 – ~Jun 2019 · 7 months · monthly snapshot~Jun 2019 – ~Feb 2020 · 8 months · monthly snapshot~Feb 2020 – ~Mar 2020 · 29 days · monthly snapshot~Mar 2020 – ~Sep 2020 · 6 months · monthly snapshot~Sep 2020 – ~Jan 2021 · 4 months · monthly snapshot~Jan 2021 – ~Feb 2021 · 31 days · monthly snapshot~Feb 2021 – ~Oct 2021 · 8 months · monthly snapshot~Oct 2021 – ~Feb 2022 · 4 months · monthly snapshot~Feb 2022 – ~Feb 2023 · 12 months · monthly snapshot~Feb 2023 – ~Mar 2024 · 13 months · monthly snapshot~Mar 2024 – ~Jul 2024 · 4 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – present · 16 months · monthly snapshot

Change History

18 versions recorded

  1. Mar 2025 — Present [monthly]

    Active Not Recruiting PHASE1

  2. Sep 2024 — Mar 2025 [monthly]

    Active Not Recruiting PHASE1

  3. Jul 2024 — Sep 2024 [monthly]

    Active Not Recruiting PHASE1

  4. Mar 2024 — Jul 2024 [monthly]

    Active Not Recruiting PHASE1

  5. Feb 2023 — Mar 2024 [monthly]

    Active Not Recruiting PHASE1

▶ Show 13 earlier versions

  1. Feb 2022 — Feb 2023 [monthly]

    Active Not Recruiting PHASE1

  2. Oct 2021 — Feb 2022 [monthly]

    Active Not Recruiting PHASE1

  3. Feb 2021 — Oct 2021 [monthly]

    Active Not Recruiting PHASE1

  4. Jan 2021 — Feb 2021 [monthly]

    Active Not Recruiting PHASE1

  5. Sep 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE1

  6. Mar 2020 — Sep 2020 [monthly]

    Active Not Recruiting PHASE1

  7. Feb 2020 — Mar 2020 [monthly]

    Active Not Recruiting PHASE1

  8. Jun 2019 — Feb 2020 [monthly]

    Active Not Recruiting PHASE1

  9. Nov 2018 — Jun 2019 [monthly]

    Active Not Recruiting PHASE1

  10. Jun 2018 — Nov 2018 [monthly]

    Active Not Recruiting PHASE1

  11. May 2018 — Jun 2018 [monthly]

    Active Not Recruiting PHASE1

  12. Feb 2017 — May 2018 [monthly]

    Active Not Recruiting PHASE1

  13. Jan 2017 — Feb 2017 [monthly]

    Active Not Recruiting PHASE1

    First recorded

Aug 2013

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Baylor College of Medicine
  • Center for Cell and Gene Therapy, Baylor College of Medicine
  • Kids Cancer Research Foundation
  • National Cancer Institute (NCI)
  • Solving Kids' Cancer
  • The Evan Foundation
  • The Methodist Hospital Research Institute
Data source: Baylor College of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations